21.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.57
Aprire:
$21.83
Volume 24 ore:
627.84K
Relative Volume:
0.91
Capitalizzazione di mercato:
$590.07M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-18.73
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
+10.42%
1M Prestazione:
+20.12%
6M Prestazione:
+110.97%
1 anno Prestazione:
+5.33%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARCT
Arcturus Therapeutics Holdings Inc
|
21.73 | 577.03M | 157.75M | -29.73M | -21.00M | -1.16 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-04 | Ripresa | H.C. Wainwright | Buy |
2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
2025-01-28 | Iniziato | BTIG Research | Buy |
2024-08-12 | Iniziato | Leerink Partners | Outperform |
2023-12-13 | Iniziato | Canaccord Genuity | Buy |
2023-07-24 | Iniziato | William Blair | Outperform |
2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2022-11-14 | Ripresa | Wells Fargo | Overweight |
2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
2021-08-11 | Downgrade | Goldman | Neutral → Sell |
2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
2021-06-25 | Ripresa | Goldman | Neutral |
2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-07 | Iniziato | Wells Fargo | Overweight |
2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
2020-12-08 | Reiterato | B. Riley Securities | Buy |
2020-12-07 | Reiterato | B. Riley Securities | Buy |
2020-10-26 | Iniziato | Barclays | Overweight |
2020-10-06 | Iniziato | Citigroup | Buy |
2020-08-26 | Iniziato | Piper Sandler | Overweight |
2020-07-30 | Ripresa | ROTH Capital | Buy |
2020-07-16 | Iniziato | Raymond James | Outperform |
2020-07-13 | Iniziato | B. Riley FBR | Buy |
2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
2020-02-11 | Iniziato | Robert W. Baird | Outperform |
2020-02-07 | Iniziato | Guggenheim | Buy |
2020-02-06 | Iniziato | Guggenheim | Buy |
2019-04-05 | Iniziato | H.C. Wainwright | Buy |
2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Is it time to cut losses on Arcturus Therapeutics Holdings Inc.Weekly Trade Analysis & Verified Momentum Watchlists - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comebackDollar Strength & Short-Term Trading Alerts - newser.com
What dividend safety score for Arcturus Therapeutics Holdings Inc. stockTrend Reversal & High Conviction Trade Alerts - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockBuy Signal & Accurate Entry and Exit Point Alerts - newser.com
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? - sharewise.com
Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Real time social sentiment graph for Arcturus Therapeutics Holdings Inc.July 2025 Breakouts & Expert Verified Stock Movement Alerts - newser.com
Using data models to predict Arcturus Therapeutics Holdings Inc. stock movement - newser.com
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuationJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Published on: 2025-10-13 07:05:21 - newser.com
Arcturus Therapeutics Holdings Inc. stock chart pattern explainedQuarterly Profit Review & Long-Term Capital Growth Strategies - newser.com
What MACD and RSI say about Arcturus Therapeutics Holdings Inc.Fed Meeting & Weekly Momentum Picks - newser.com
Technical analysis overview for Arcturus Therapeutics Holdings Inc. stockJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Arcturus Therapeutics (ARCT) Anticipated to Benefit from Upcomin - GuruFocus
Published on: 2025-10-10 03:52:17 - newser.com
Applying chart zones and confluence areas to Arcturus Therapeutics Holdings Inc.2025 Market Overview & Verified High Yield Trade Plans - newser.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
How to use Fibonacci retracement on Arcturus Therapeutics Holdings Inc.Quarterly Performance Summary & Technical Pattern Based Signals - newser.com
Is this a good reentry point in Arcturus Therapeutics Holdings Inc.July 2025 Selloffs & Free High Return Stock Watch Alerts - newser.com
Arcturus Stock Rockets From $9 To $18 In 5 MonthsAll Eyes On Upcoming Cystic Fibrosis Data - RTTNews
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 225% Potential Upside - DirectorsTalk Interviews
Published on: 2025-10-09 02:58:21 - newser.com
Is Arcturus Therapeutics Holdings Inc a good long term investmentChart Pattern Recognition & Double Or Triple Investment - earlytimes.in
Arcturus Therapeutics Holdings Inc Stock Analysis and ForecastBollinger Bands Signals & Investor Community Interactions - earlytimes.in
Public Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.7%Should You Sell? - MarketBeat
What high frequency data says about Arcturus Therapeutics Holdings Inc.Quarterly Risk Review & Weekly Top Gainers Alerts - newser.com
Does Arcturus Therapeutics Holdings Inc. fit your quant trading modelTrade Risk Summary & Long-Term Capital Growth Ideas - newser.com
Arcturus Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Best data tools to analyze Arcturus Therapeutics Holdings Inc. stockJuly 2025 Summary & Verified Technical Signals - newser.com
Arcturus Therapeutics Holdings (ARCT): An Investor's Insight Into A Potential 236% Upside - DirectorsTalk Interviews
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap UpHere's What Happened - MarketBeat
High Growth Tech Stocks In The US For September 2025 - simplywall.st
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 9.7%Here's What Happened - MarketBeat
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):